Capsida Biotherapeutics

Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration

Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties 7 January 2025 — California, US — Capsida Biotherapeutics today announced that AbbVie has exercised an option for the first neurodegenerative disease program under their ongoing collaboration. Capsida will receive a $40 million license payment and is eligible for…
1300 Rancho Conejo Blvd. Thousand Oaks, CA 91320